72 related articles for article (PubMed ID: 26556626)
41. Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach.
Pagano K; Listro R; Linciano P; Rossi D; Longhi E; Taraboletti G; Molinari H; Collina S; Ragona L
Bioorg Chem; 2023 Jul; 136():106529. PubMed ID: 37084585
[TBL] [Abstract][Full Text] [Related]
42. FGF2 as an autocrine growth factor for immortal human breast epithelial cells.
Souttou B; Hamelin R; Crépin M
Cell Growth Differ; 1994 Jun; 5(6):615-23. PubMed ID: 8086338
[TBL] [Abstract][Full Text] [Related]
43. Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors.
Dias MH; Fonseca CS; Zeidler JD; Albuquerque LL; da Silva MS; Cararo-Lopes E; Reis MS; Noël V; Dos Santos EO; Prior IA; Armelin HA
Mol Oncol; 2019 Feb; 13(2):290-306. PubMed ID: 30422399
[TBL] [Abstract][Full Text] [Related]
44. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.
Jin L; Nonaka Y; Miyakawa S; Fujiwara M; Nakamura Y
Mol Ther; 2016 Nov; 24(11):1974-1986. PubMed ID: 27506449
[TBL] [Abstract][Full Text] [Related]
45. Cyclic and dimeric fibroblast growth factor 2 variants with high biomedical potential.
Krzyscik MA; Opaliński Ł; Szymczyk J; Otlewski J
Int J Biol Macromol; 2022 Oct; 218():243-258. PubMed ID: 35878661
[TBL] [Abstract][Full Text] [Related]
46. Serine protease PRSS23 drives gastric cancer by enhancing tumor associated macrophage infiltration
Qin S; Wang Z; Huang C; Huang P; Li D
Front Immunol; 2022; 13():955841. PubMed ID: 36189305
[TBL] [Abstract][Full Text] [Related]
47. Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay.
Benham V; Bullard B; Dexheimer TS; Bernard MP; Neubig RR; Liby KT; Bernard JJ
Sci Rep; 2019 Jul; 9(1):10278. PubMed ID: 31311976
[TBL] [Abstract][Full Text] [Related]
48. Half-life modeling of basic fibroblast growth factor released from growth factor-eluting polyelectrolyte multilayers.
Ding I; Peterson AM
Sci Rep; 2021 May; 11(1):9808. PubMed ID: 33963247
[TBL] [Abstract][Full Text] [Related]
49. Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model.
Krzyscik MA; Zakrzewska M; Sørensen V; Øy GF; Brunheim S; Haugsten EM; Mælandsmo GM; Wiedlocha A; Otlewski J
Biomacromolecules; 2021 Oct; 22(10):4169-4180. PubMed ID: 34542998
[TBL] [Abstract][Full Text] [Related]
50. Structural analysis of a glucoglucuronan derived from laminarin and the mechanisms of its anti-lung cancer activity.
Jin W; He X; Wu W; Bao Y; Wang S; Cai M; Zhang W; Wang C; Zhang F; Linhardt RJ; Mao G; Zhong W
Int J Biol Macromol; 2020 Nov; 163():776-787. PubMed ID: 32653371
[TBL] [Abstract][Full Text] [Related]
51. FGF2 causes genomic instability.
Stone L
Nat Rev Urol; 2018 Sep; 15(9):528. PubMed ID: 29977055
[No Abstract] [Full Text] [Related]
52. Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value.
Ardizzone A; Bova V; Casili G; Repici A; Lanza M; Giuffrida R; Colarossi C; Mare M; Cuzzocrea S; Esposito E; Paterniti I
Cells; 2023 Mar; 12(7):. PubMed ID: 37048074
[TBL] [Abstract][Full Text] [Related]
53. Peptidomimetics in cancer targeting.
Gomari MM; Abkhiz S; Pour TG; Lotfi E; Rostami N; Monfared FN; Ghobari B; Mosavi M; Alipour B; Dokholyan NV
Mol Med; 2022 Dec; 28(1):146. PubMed ID: 36476230
[TBL] [Abstract][Full Text] [Related]
54. MicroRNA-936 targets FGF2 to inhibit epithelial ovarian cancer aggressiveness by deactivating the PI3K/Akt pathway.
Li C; Yu S; Wu S; Ni Y; Pan Z
Onco Targets Ther; 2019; 12():5311-5322. PubMed ID: 31371979
[TBL] [Abstract][Full Text] [Related]
55. LC-0882 targets PAK4 and inhibits PAK4-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells.
Zhang HY; Zhang J; Hao CZ; Zhou Y; Wang J; Cheng MS; Zhao DM; Li F
Am J Transl Res; 2017; 9(6):2736-2747. PubMed ID: 28670365
[TBL] [Abstract][Full Text] [Related]
56. Peptidomimetic suppresses proliferation and invasion of gastric cancer cells by fibroblast growth factor 2 signaling cascade blockage.
Li W; Du X; Chen Q; Kang Y; Xu C; Fan L; Ye H; Ying S; Shi L; Jin R; Wu J; Liang G; Li X
Anticancer Drugs; 2016 Mar; 27(3):164-72. PubMed ID: 26556626
[TBL] [Abstract][Full Text] [Related]
57. The therapeutic potential of a novel non-ATP-competitive fibroblast growth factor receptor 1 inhibitor on gastric cancer.
Xu C; Li W; Qiu P; Xia Y; Du X; Wang F; Shen L; Chen Q; Zhao Y; Jin R; Wu J; Liang G; Li X
Anticancer Drugs; 2015 Apr; 26(4):379-87. PubMed ID: 25521558
[TBL] [Abstract][Full Text] [Related]
58. A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.
Fan L; Li W; Ying S; Shi L; Wang Z; Chen G; Ye H; Wu X; Wu J; Liang G; Li X
Tumour Biol; 2015 Sep; 36(9):7233-41. PubMed ID: 25894376
[TBL] [Abstract][Full Text] [Related]
59. The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo.
Yu Y; Gao S; Li Q; Wang C; Lai X; Chen X; Wang R; Di J; Li T; Wang W; Wu X
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1321-8. PubMed ID: 22481251
[TBL] [Abstract][Full Text] [Related]
60. FGF signaling network in the gastrointestinal tract (review).
Katoh M; Katoh M
Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
